OBJECTIVE
Osteolytic jaw lesions are heterogeneous and share radiographic features. Radiomics from CBCT may provide quantitative biomarkers to aid differential diagnosis between developmental and inflammatory Odontogenic Cysts.
METHODS
A retrospective radiomic analysis was performed on CBCT scans of osteolytic jaw lesions from 52 patients; after quality control, 44 lesions were included (28 developmental and 16 inflammatory cysts). Lesions were segmented in 3D Slicer, and radiomic features were extracted with PyRadiomics. Unsupervised analyses used K-means and principal component analysis (PCA). Group differences were tested with ANOVA. For supervised classification, Logistic Regression, Random Forest, SVM, Multilayer Perceptron, and a stacking model were trained using PCA-based dimensionality reduction, mutual-information feature selection, SMOTE oversampling, and repeated stratified 5-fold cross-validation.
RESULTS
One thousand four hundred and thirty-seven features per lesion were extracted; univariate analysis identified 11 radiomic features showing differences between the two diagnostic groups (p < 0.05). However, none remained statistically significant after false discovery rate (FDR) correction, indicating the exploratory nature of these findings. Random Forest showed the best performance (AUC 0.76, accuracy 0.74, specificity 0.81, sensitivity 0.61). Unsupervised clustering did not reveal separated groups.
CONCLUSIONS
While individual radiomic features did not demonstrate significance, a multivariate machine learning approach may identify complex signatures with moderate discriminative performance.
Pierluigi Mariani, Francesco Fanelli, Diana Russo et al.· Oral Diseases· 0 citations
Cancer remains a highly complex and heterogeneous disease, causing major morbidity and mortality worldwide despite advances in diagnosis and treatment. The hallmarks of cancer enlighten the biological mechanisms supporting tumourigenesis and malignant evolution, while helping to identify potential therapeutic targets. Medical cannabis has mostly been used in oncology for supportive care, but increasing preclinical evidence suggests interference with cancer-related signalling pathways. This narrative review summarizes the current evidence on cannabinoids, in particular the phytocannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), framing their prospective anticancer effects in the hallmarks of cancer. Preclinical studies imply that CBD exerts antiproliferative effects by modulating oncogenic signalling pathways, including EGFR, PI3K/AKT, RAS/RAF/ERK, mTOR and Wnt/β-catenin, while also influencing tumour suppressor pathways involving p53, p21 and p27, causing cell cycle arrest. CBD has additionally been shown to promote programmed cell death via mitochondrial dysfunction and autophagy, altering cancer metabolism as well. Furthermore, CBD has shown anti-invasive and antiangiogenic properties and also appears to modulate immune responses and interactions with the tumour microenvironment, including emerging links with the microbiome. Overall, cannabinoids exhibit biologically plausible antitumour activity across multiple cancer hallmarks and may present promising candidates for combination therapeutic strategies. Nonetheless, the current evidence remains predominantly preclinical, and robust translational studies and clinical trials are needed to clarify their pharmacokinetic and pharmacodynamic profiles, determine their clinical efficacy and safety while assessing their potential integration into multimodal cancer treatment.
Diana Russo, Rute Fernandes, Valéria Tavares et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
